Cardiac Sarcoidosis: Utilizing Cardiac MRI and PET-CT

Kamari Ositelu,Sonu Abraham,Ike S. Okwuosa

DOI: https://doi.org/10.1007/s11886-024-02093-8

IF: 3.955

2024-07-18

Current Cardiology Reports

Abstract:Cardiac sarcoidosis is an inflammatory condition that has been associated with deleterious cardiac manifestations. The diagnosis of cardiac sarcoidosis is challenging and can be guided by advanced cardiac imaging.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

Revealing The Enigma Of Cardiac Sarcoidosis: The Crucial Significance Of Advanced Imaging Modalities- A Case Report

Resha Khanal,Sharad Oli,Luis Afonso,Lobelia Samavati

DOI: https://doi.org/10.1016/j.cardfail.2023.10.129

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Background Cardiac sarcoidosis (CS) can present with various symptoms including heart failure, arrhythmias or sudden cardiac death. Due to this diverse presentation, the management can be challenging. We present a case of CS illuminating the significance of multimodality imaging techniques. Case 26-year male with biopsy proven pulmonary sarcoidosis presented with palpitation and lightheadedness. EKG showed ventricular tachycardia (VT). Left Heart Catheterization showed nonobstructive coronaries. Cardiac MRI (CMR) with Delayed Hyper-Enhancement (DHE) images showed areas of fibrosis mostly in the septum and active inflammation mostly in the inferolateral and anterolateral wall consistent with CS. ICD was placed to prevent VT. Subsequently, Positron Emission Tomography (PET) scan was performed that showed significant diffuse uptake of the radiotracer in the left ventricular myocardium which demonstrated active CS. Patient was initially started on methotrexate and treatment was later escalated to infliximab with improvement of symptoms. Discussion Approximately 5% of patients with sarcoidosis experience CS. The clinical features, laboratory biomarkers, and traditional imaging findings have their limitations. The 2014 Heart Rhythm Society (HRS) Expert Consensus guideline includes both PET scan and CMR to increase diagnostic yield. CMR uses Late Gadolinium Enhancement (LGE) to assess function and identify fibrosis, while 18F-FDG PET scan uses 18F-FDG to assess myocardial inflammation. A study by Vita et.al showed that one third of LGE positive patients had no FDG uptake on PET scan. This concluded that CMR and PET provide complementary value in guiding further management as they assess different pathophysiology of the disease as evident in our case. Thus, our patient received a combination of ICD placement for scarring and anti-inflammatory agent for active inflammation. The amount of myocardial late enhancement detected during CMR is correlated with impaired left ventricular function and has prognostic implications. Blankstein et al. concluded that abnormal FDG uptake and perfusion defects are associated with higher risk of VT and death. Conclusion Randomized control trials are needed to standardize CS diagnostic criteria with PET and CMR, preventing under-diagnosis and guiding further management.

cardiac & cardiovascular systems
Imaging of Cardiac Sarcoidosis: An Update and Future Aspects

Petar Saric,John P. Bois,John R. Giudicessi,Andrew N. Rosenbaum,Joanna E. Kusmirek,Grace Lin,Panithaya Chareonthaitawee

DOI: https://doi.org/10.1053/j.semnuclmed.2024.02.004

IF: 4.802

2024-03-14

Seminars in Nuclear Medicine

Abstract:Cardiac sarcoidosis (CS), an increasingly recognized disease of unknown etiology, is associated with significant morbidity and mortality. Given the limited diagnostic yield of traditional endomyocardial biopsy (EMB), there is increasing reliance on multimodality cardiovascular imaging in the diagnosis and management of CS, with EMB being largely supplanted by the use of 18 F-fluorodeoxyglucose (FDG-PET) and cardiac magnetic resonance imaging (CMR). This article aims to provide a comprehensive review of imaging modalities currently utilized in the screening, diagnosis, and monitoring of CS, while highlighting the latest developments in each area.

radiology, nuclear medicine & medical imaging
Contemporary Diagnostics of Cardiac Sarcoidosis: The Importance of Multimodality Imaging

Mihailo Stjepanovic,Filip Markovic,Ivan Milivojevic,Spasoje Popevic,Sanja Dimic-Janjic,Viseslav Popadic,Dimitrije Zdravkovic,Maja Popovic,Andrea Klasnja,Aleksandra Radojevic,Dusan Radovanovic,Marija Zdravkovic

DOI: https://doi.org/10.3390/diagnostics14171865

IF: 3.6

2024-08-27

Diagnostics

Abstract:Sarcoidosis is an inflammatory condition that can affect multiple organ systems and is characterized by the formation of non-caseating granulomas in various organs, including the heart. Due to suboptimal diagnostic rates, the true prevalence and incidence of cardiac sarcoidosis (CS) remain to be determined. In patients with suspected CS, an initial examination should include 12-lead ECG or ambulatory ECG monitoring, and echocardiography with the estimation of LV, RV function, and strain rate. In patients with confirmed extracardiac sarcoidosis and with high clinical suspicion for CS, sophisticated imaging modalities, including cardiac MRI and PET, are indicated. Typical inflammation patterns and myocardial scarring should pose a high suspicion for CS. In patients without diagnosed extracardiac sarcoidosis and high clinical suspicion, although with low diagnostic probability, an endomyocardial biopsy should be considered to establish the diagnosis of definite isolated cardiac sarcoidosis. Timely diagnosis enables the initiation of therapy and close monitoring of adverse cardiac events that can be life-threatening, including sudden cardiac death, ventricular tachycardia, high-degree AV block, and heart failure. Implementing biomarkers in correlation to cardiac imaging can determine the disease's severity and progression but can also be helpful in following the treatment response. The formation of larger global registries can be helpful in the identification of independent predictors of adverse clinical events and the development of specific diagnostic algorithms to reduce the overall risk of this serious condition.

medicine, general & internal
Sarcoid heart disease and imaging

Jian Liang Tan,Gregory E Supple,Saman Nazarian

DOI: https://doi.org/10.1016/j.hroo.2023.11.012

2023-11-19

Heart Rhythm O2

Abstract:Cardiac sarcoidosis (CS) can mimic any cardiomyopathy due to its ability to manifest with a variety of clinical presentations. The exact prevalence of CS remains unknown but has been reported ranging from 2.3% to as high as 29.9% among patients presenting with new onset cardiomyopathy and/or atrioventricular block. Early and accurate diagnosis of CS is often challenging due to the nature of disease progression and lack of diagnostic reference standard. The current diagnostic criteria for CS are lacking in sensitivity and specificity. Here, we review the contemporary role of advanced imaging modalities such as cardiac magnetic resonance imaging and positron emission tomography/computed tomography imaging in diagnosing and prognosticating patients with CS.
Cardiac Sarcoidosis—Diagnostic and Therapeutic Challenges

Dennis Korthals,Michael Bietenbeck,Hilke Könemann,Florian Doldi,David Ventura,Michael Schäfers,Michael Mohr,Julian Wolfes,Felix Wegner,Ali Yilmaz,Lars Eckardt

DOI: https://doi.org/10.3390/jcm13061694

IF: 3.9

2024-03-16

Journal of Clinical Medicine

Abstract:Sarcoidosis is a multisystem disorder of unknown etiology. The leading hypothesis involves an antigen-triggered dysregulated T-cell-driven immunologic response leading to non-necrotic granulomas. In cardiac sarcoidosis (CS), the inflammatory response can lead to fibrosis, culminating in clinical manifestations such as atrioventricular block and ventricular arrhythmias. Cardiac manifestations frequently present as first and isolated signs or may appear in conjunction with extracardiac manifestations. The incidence of sudden cardiac death (SCD) is high. Diagnosis remains a challenge. For a definite diagnosis, endomyocardial biopsy (EMB) is suggested. In clinical practice, compatible findings in advanced imaging using cardiovascular magnetic resonance (CMR) and/or positron emission tomography (PET) in combination with extracardiac histological proof is considered sufficient. Management revolves around the control of myocardial inflammation by employing immunosuppression. However, data regarding efficacy are merely based on observational evidence. Prevention of SCD is of particular importance and several guidelines provide recommendations regarding device therapy. In patients with manifest CS, outcome data indicate a 5-year survival of around 90% and a 10-year survival in the range of 80%. Data for patients with silent CS are conflicting; some studies suggest an overall benign course of disease while others reported contrasting observations. Future research challenges involve better understanding of the immunologic pathogenesis of the disease for a targeted therapy, improving imaging to aid early diagnosis, assessing the need for screening of asymptomatic patients and randomized trials.

medicine, general & internal
[Cardiac sarcoidosis: a diagnostic and therapeutic challenge]

Sabine Ammann,Arnaud Dominati,Philippe Meyer,Etienne Pruvot,Camillo Ribi,Jörg Seebach

DOI: https://doi.org/10.53738/REVMED.2024.20.868.682

2024-04-03

Abstract:The diagnosis of cardiac sarcoidosis, particularly in its isolated cardiac form, represents a major challenge due to non-specific symptoms and the limited sensitivity and specificity of basic cardiac investigations. MRI and metabolic PET-CT are important elements in the diagnostic process. Corticosteroids remain the cornerstone for the treatment of the inflammatory phase, in association with biological agents and steroid-sparing therapies. The goal is to limit the progression of fibrosis, which is a source of malignant arrhythmias and heart failure. The indication for implantation of a cardiac defibrillator must be carefully evaluated to reduce the risk of sudden death. Multidisciplinary collaboration is essential for optimal care.
Exploring the latest advances in 18F-FDG PET/CT and cardiac magnetic resonance for imaging for cardiac sarcoidosis diagnosis

Seyedeh Nooshin Miratashi Yazdi,Farshad Riahi,Sara Azizollahi,Seyed Hamed Tooyserkani,Shahin Fesharaki,Maryam Alaei,Mohamad Ghazanfari Hashemi,Milad Vakili Zarch,Azad Mojahedi

DOI: https://doi.org/10.62347/GIKK5707

2024-04-25

Abstract:Sarcoidosis is a systemic inflammatory disease that affects multiple organs. Various clinical signs are associated with cardiac sarcoidosis (CS), and the diagnosis process is complicated because any organ could be involved. Despite the critical clinical importance of early and precise diagnosis of CS, there is currently no gold-standard method for CS evaluation. The non-invasive imaging modalities of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and cardiac magnetic resonance (CMR) imaging have demonstrated the potential for identifying various histological characteristics of CS. Recently, the development of hybrid FDG-PET/CMR scanners has enabled the simultaneous acquisition of these attributes. Compared to just one imaging modality, these scanners detect CS and stratify risk more accurately and with higher sensitivity. Analyzing the potential role of concurrent FDG-PET/CMR in enhancing the diagnosis of CS, the present review concentrates on the advantages of this technique in light of recent technological developments.
Cardiac sarcoidosis: diagnosis and management

Abdullah Aftab,Stanley Szeto,Zoha Aftab,Sabahat Bokhari

DOI: https://doi.org/10.3389/fcvm.2024.1394075

IF: 3.6

2024-10-09

Frontiers in Cardiovascular Medicine

Abstract:Non-caseating granulomatous infiltration of the myocardium is the hallmark of cardiac sarcoidosis (CS). CS manifests clinically as conduction disturbance, ventricular arrhythmia, sudden cardiac death and/or heart failure with reduced ejection fraction. Other than confirmation through endomyocardial biopsy, a diagnosis of probable CS can be established by histological evidence of systemic sarcoidosis in addition to characteristic clinical or advanced imaging findings. Cardiac Magnetic Resonance imaging (CMR) and 18 F-flurodeoxyglycose positron emission tomography (FDG-PET) are imaging modalities indispensable in the diagnosis and monitoring of CS. FDG-PET is the method of choice for identifying the active inflammatory phase of CS and in the monitoring and modifying of immunosuppressive treatment. CMR is better suited for assessing cardiac morphology and function. Both modalities are more effective in detecting CS when used in combination than either is alone. Management of CS is primarily based upon observational data of low quality due to a paucity of randomized controlled trials. Corticosteroid therapy and/or tiered-immunosuppression are the mainstays of treatment in reducing myocardial inflammation. Steroid-sparing agents aim to limit the unfavorable side-effects of a significant steroid burden. Antiarrhythmics and guideline-directed medical therapies are utilized for control of ventricular arrhythmia and left ventricular dysfunction respectively. CS necessitates multidisciplinary care in specialized centers to most effectively diagnose and manage the disease. Additional randomized trials are warranted to further our understanding of medical optimization in CS.

cardiac & cardiovascular systems
Intense 68Ga-OncoFAP Uptake as a New Promising Diagnostic Biomarker in Cardiac Sarcoidosis

David Ventura,Michael Schäfers,Ali Yilmaz,Lars Eckardt,Dennis Korthals

DOI: https://doi.org/10.1097/rlu.0000000000005214

IF: 10.6

2024-05-05

Clinical Nuclear Medicine

Abstract:A 72-year-old man revealed typical findings of cardiac sarcoidosis on cardiovascular MRI. However, 18F-FDG PET showed no hypermetabolism. Therefore, immunosuppression was not initiated. After 2 years, ventricular arrhythmias and heart failure worsened. 68Ga–fibroblast activation protein inhibitor PET was initiated to evaluate potential adverse remodeling due to progressive myocardial fibrosis. A second 18F-FDG PET still revealed no hypermetabolism, and the patient received an implanted cardioverter defibrillator after electrophysiological risk stratification. We present a case of intense fibroblast activation despite a missing 18F-FDG uptake (mismatch).

radiology, nuclear medicine & medical imaging
Risk Stratification in Cardiac Sarcoidosis With Cardiac Positron Emission Tomography: A Systematic Review and Meta-Analysis

Tahir S Kafil,Omar M Shaikh,Yehia Fanous,Joseph Benjamen,Muhammad M Hashmi,Abdulazeez Jawad,Tahir Dahrouj,Rami M Abazid,Mina Swiha,Jonathan Romsa,Rob S B Beanlands,Terrence D Ruddy,Lisa Mielniczuk,David H Birnie,Nikolaos Tzemos

DOI: https://doi.org/10.1016/j.jcmg.2024.05.013

Abstract:Background: Although positron emission tomography (PET) imaging is well established for its diagnostic role in cardiac sarcoidosis, less is known about the prognostic value of PET and its use in risk stratification for major adverse cardiac events (MACE). Objectives: The goal of this study was to perform a systematic review and meta-analysis looking at the prognostic value of PET imaging in patients with cardiac sarcoidosis. Methods: Study investigators systematically searched EMBASE (Excerpta Medica dataBASE), MEDLINE, PubMed, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, CINAHL (Cumulative Index to Nursing and Allied Health Literature), ClinicalTrials.gov, and the European Union Clinical Trial Registry for cardiac sarcoidosis and PET imaging. The primary outcome of interest was MACE. Results: The search revealed 3,010 records, of which 55 studies were included. This represented 5,250 patients. Factors associated with MACE included the following: the combination of abnormal fluorodeoxyglucose (FDG) uptake and perfusion defect, which had an OR of 2.86 (95% CI: 1.74-4.71; P < 0.0001); abnormal perfusion or FDG uptake, which had an OR of 2.69 (95% CI: 1.67-4.33); abnormal FDG uptake, which had an OR of 2.61 (95% CI: 1.51-4.50); focal abnormal right ventricular uptake, which had an OR of 6.27 (95% CI: 3.19-12.32; P < 0.00001); and a lack of response to immunosuppression on serial PET, which had an OR of 8.43 (95% CI: 3.25-21.85; P < 0.0001). A QUIPS (Quality in Prognostic Studies) tool analysis found a low to moderate risk of bias, particularly given the small sample sizes in the individual studies. Conclusions: Multiple cardiac PET parameters provide risk stratification value in cardiac sarcoidosis. Focal right ventricular uptake and a lack of response to immunosuppressive therapy on serial PET imaging were particularly predictive of MACE.
Potential application of 68Ga-FAPI PET/CT for diagnosing cardiac sarcoidosis

Ritanshu Solanki,Harpreet Singh,Vansha Mehta,Prashant Panda,Manphool Singhal,Ashwani Sood,Bhagwant Rai Mittal

DOI: https://doi.org/10.1016/j.nuclcard.2024.101835

Abstract:Detecting cardiac sarcoidosis; a potentially life-threatening condition is challenging and requires a multimodality imaging approach using echocardiography, PET/CT and CMR. Although 18F-FDG is the recommended PET tracer for evaluating cardiac sarcoidosis, it is limited by physiological cardiac FDG uptake and requires stringent patient preparation/ dietary modifications before imaging. We hereby present a case of cardiac sarcoidosis demonstrating myocardial FAPI uptake on cardiac PET, highlighting the potential role of 68Ga-FAPI PET in the evaluation of cardiac sarcoidosis.
Cardiac Sarcoidosis: A Comprehensive Clinical Review

András Vereckei,Zsuzsanna Besenyi,Viktória Nagy,Bence Radics,Hajnalka Vágó,Zsigmond Jenei,Gábor Katona,Róbert Sepp

DOI: https://doi.org/10.31083/j.rcm2502037

2024-01-29

Reviews in Cardiovascular Medicine

Abstract:Sarcoidosis is an inflammatory multisystemic disease of unknown etiology characterized by the formation of non-caseating granulomas. Sarcoidosis can affect any organ, predominantly the lungs, lymphatic system, skin and eyes. While >90% of patients with sarcoidosis have lung involvement, an estimated 5% of patients with sarcoidosis have clinically manifest cardiac sarcoidosis (CS), whereas approximately 25% have asymptomatic, clinically silent cardiac involvement verified by autopsy or imaging studies. CS can present with conduction disturbances, ventricular arrhythmias, heart failure or sudden cardiac death. Approximately 30% of <60-year-old patients presenting with unexplained high degree atrioventricular (AV) block or ventricular tachycardia are diagnosed with CS, therefore CS should be strongly considered in such patients. CS is the second leading cause of death among patients affected by sarcoidosis after pulmonary sarcoidosis, therefore its early recognition is important, because early treatment may prevent death from cardiovascular involvement. The establishment of isolated CS diagnosis sometimes can be quite difficult, when extracardiac disease cannot be verified. The other reason for the difficulty to diagnose CS is that CS is a chameleon of cardiology and it can mimic (completely or almost completely) different cardiac diseases, such as arrhythmogenic cardiomyopathy, giant cell myocarditis, dilated, restrictive and hypertrophic cardiomyopathies. In this review article we will discuss the current diagnosis and management of CS and delineate the potential difficulties and pitfalls of establishing the diagnosis in atypical cases of isolated CS.

cardiac & cardiovascular systems
FDG PET/CT Imaging of Sarcoidosis.

K. Benali,F. Rouzet,C. Régis

DOI: https://doi.org/10.1053/j.semnuclmed.2022.08.004

IF: 4.802

2022-09-01

Seminars in Nuclear Medicine

Abstract:Sarcoidosis is a multisystemic granulomatous disease of unknown etiology. The diagnostic can be made by histological identification of non-caseous granuloma or by a combination of clinical criteria. Active inflammatory granuloma can lead to fibrotic damage. Although 50% of cases resolve spontaneously, systemic treatments are often necessary to decrease symptoms and avoid permanent organ dysfunction, notably in cardiac sarcoidosis. The course of the disease can be punctuated by exacerbations and relapses and the prognostic depends mainly on affected sites and patient management. FDG-PET/CT along with newer FDG-PET/MR have emerged as key imaging modalities in sarcoidosis, namely for certain diagnostic purposes, staging and biopsy guiding. By identifying with a high sensitivity inflammatory active granuloma, FDG hybrid imaging is a main prognostic tool and therapeutic ally in sarcoidosis. This review aims to highlight the actual critical roles of hybrid PET imaging in sarcoidosis and display a brief perspective for the future which appears to include other radiotracers and artificial intelligence applications.

Medicine
Isolated cardiac sarcoidosis: A clinical challenge

Paul Njoku,Sumbal Rani,Orestis Paschalis,Emanuela Alati,Amit K J Mandal,Constantinos G Missouris

DOI: https://doi.org/10.1016/j.clinme.2024.100245

2024-09-19

Abstract:Sarcoidosis is an inflammatory disease characterised by non-caseating granulomas of unclear aetiology. Isolated cardiac sarcoidosis (ICS) is rare and occurs when there is granulomatous infiltration of myocardial tissue without evidence of extracardiac sarcoidosis. The heterogeneity in clinical manifestations often presents a diagnostic challenge which leads to delays in treatment initiation. Our case highlights the often quiescent presentation of ICS, the importance of early treatment and the diagnostic challenges that contribute to its underdiagnosis.
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association

Richard K. Cheng,Michelle M. Kittleson,Craig J. Beavers,David H. Birnie,Ron Blankstein,Paco E. Bravo,Nisha A. Gilotra,Marc A. Judson,Kristen K. Patton,Leonie Rose-Bovino,

DOI: https://doi.org/10.1161/cir.0000000000001240

IF: 37.8

2024-04-18

Circulation

Abstract:Cardiac sarcoidosis is an infiltrative cardiomyopathy that results from granulomatous inflammation of the myocardium and may present with high-grade conduction disease, ventricular arrhythmias, and right or left ventricular dysfunction. Over the past several decades, the prevalence of cardiac sarcoidosis has increased. Definitive histological confirmation is often not possible, so clinicians frequently face uncertainty about the accuracy of diagnosis. Hence, the likelihood of cardiac sarcoidosis should be thought of as a continuum (definite, highly probable, probable, possible, low probability, unlikely) rather than in a binary fashion. Treatment should be initiated in individuals with clinical manifestations and active inflammation in a tiered approach, with corticosteroids as first-line treatment. The lack of randomized clinical trials in cardiac sarcoidosis has led to treatment decisions based on cohort studies and consensus opinions, with substantial variation observed across centers. This scientific statement is intended to guide clinical practice and to facilitate management conformity by providing a framework for the diagnosis and management of cardiac sarcoidosis.

cardiac & cardiovascular systems,peripheral vascular disease
Hybrid Magnetic Resonance Positron Emission Tomography Is Associated With Cardiac-Related Outcomes in Cardiac Sarcoidosis

Maria Giovanna Trivieri,Philip M Robson,Vittoria Vergani,Gina LaRocca,Angelica M Romero-Daza,Ronan Abgral,Ana Devesa,Levi-Dan Azoulay,Nicolas A Karakatsanis,Aditya Parikh,Christia Panagiota,Anna Palmisano,Louis DePalo,Helena L Chang,Joseph H Rothstein,Rima A Fayad,Marc A Miller,Valentin Fuster,Jagat Narula,Marc R Dweck,Adam Morgenthau,Adam Jacobi,Maria Padilla,Jason C Kovacic,Zahi A Fayad,Philip M. Robson,Angelica M. Romero-Daza,Nicolas A. Karakatsanis,Helena L. Chang,Joseph H. Rothstein,Rima A. Fayad,Marc A. Miller,Marc R. Dweck,Jason C. Kovacic,Zahi A. Fayad

DOI: https://doi.org/10.1016/j.jcmg.2023.11.010

2024-01-01

Abstract:BACKGROUND: Imaging with late gadolinium enhancement (LGE) magnetic resonance (MR) and 18F-fluorodeoxyglucose (18F-FDG) PET allows complementary assessment of myocardial injury and disease activity and has shown promise for improved characterization of active cardiac sarcoidosis (CS) based on the combined positive imaging outcome, MR(+)PET(+).OBJECTIVES: This study aims to evaluate qualitative and quantitative assessments of hybrid MR/PET imaging in CS and to evaluate its association with cardiac-related outcomes.METHODS: A total of 148 patients with suspected CS underwent hybrid MR/PET imaging. Patients were classified based on the presence/absence of LGE (MR+/MR-), presence/absence of 18F-FDG (PET+/PET-), and pattern of 18F-FDG uptake (focal/diffuse) into the following categories: MR(+)PET(+)FOCAL, MR(+)PET(+)DIFFUSE, MR(+)PET(-), MR(-)PET(+)FOCAL, MR(-)PET(+)DIFFUSE, MR(-)PET(-). Further analysis classified MR positivity based on %LGE exceeding 5.7% as MR(+/-)5.7%. Quantitative values of standard uptake value, target-to-background ratio, target-to-normal-myocardium ratio (TNMRmax), and T2 were measured. The primary clinical endpoint was met by the occurrence of cardiac arrest, ventricular tachycardia, or secondary prevention implantable cardioverter-defibrillator (ICD) before the end of the study. The secondary endpoint was met by any of the primary endpoint criteria plus heart failure or heart block. MR/PET imaging results were compared between those meeting or not meeting the clinical endpoints.RESULTS: Patients designated MR(+)5.7%PET(+)FOCAL had increased odds of meeting the primary clinical endpoint compared to those with all other imaging classifications (unadjusted OR: 9.2 [95% CI: 3.0-28.7]; P = 0.0001), which was higher than the odds based on MR or PET alone. TNMRmax achieved an area under the receiver-operating characteristic curve of 0.90 for separating MR(+)PET(+)FOCAL from non-MR(+)PET(+)FOCAL, and 0.77 for separating those reaching the clinical endpoint from those not reaching the clinical endpoint.CONCLUSIONS: Hybrid MR/PET image-based classification of CS was statistically associated with clinical outcomes in CS. TNMRmax had modest sensitivity and specificity for quantifying the imaging-based classification MR(+)PET(+)FOCAL and was associated with outcomes. Use of combined MR and PET image-based classification may have use in prognostication and treatment management in CS.

radiology, nuclear medicine & medical imaging,cardiac & cardiovascular systems
Can FDG-PET Imaging Identify Cardiac Sarcoidosis Disease Phenotypes?

Kevin Emery Boczar,Yooyhun Park,Christiane Wiefels

DOI: https://doi.org/10.1007/s11886-024-02086-7

IF: 3.955

2024-07-13

Current Cardiology Reports

Abstract:Despite the scarcity of data, most guidelines have advocated for the treatment of cardiac sarcoidosis with corticosteroids. However, there is heterogeneity in disease presentation and response to treatment, which can make treatment challenging. The ability to identify disease phenotypes to allow for tailored therapy is therefore highly desirable. This review will seek to outline the disease phenotypes of cardiac sarcoidosis and the role that FDG-PET imaging can play in identifying these phenotypes to optimize disease diagnosis and treatment management.

cardiac & cardiovascular systems
Cardiac sarcoidosis in patients with recurrent ventricular arrhythmias refractory to endocardial ablation

Karin Nentwich,Karin Klingel,Elena Ene,Julian Müller,Arthur Berkowitz,Sebastian Barth,Thomas Deneke

DOI: https://doi.org/10.1007/s00392-024-02509-z

2024-08-27

Abstract:Introduction: The clinical presentation of cardiac sarcoidosis is diverse. Detection of granuloma in histopathological evaluation proves the diagnosis, but endomyocardial biopsy (EMB) is associated with a high sampling error. However, prompt immunosuppressive therapy may significantly affect patient's prognosis. By analyzing our single center cohort of patients with recurrent ventricular arrhythmias (VA) and nonischemic cardiomyopathy after failure of endocardial ablation, we looked for additional markers supporting the diagnosis of cardiac sarcoidosis. Method: In the last 4 years, 135 patients (mean age 49 y, 63% male) were hospitalized for epicardial ventricular arrhythmia (VA) ablation after failure of endocardial ablation. Nineteen patients had either previously received a diagnosis of cardiac sarcoidosis or were newly diagnosed. The mean follow-up time was 4.3 years. The ECG criteria, primary manifestation, histological findings in EMB, history of VT ablation, distribution of scars on MRI, electroanatomical mapping (EAM), PET CT findings, presence of atrial tachycardias, valve disease and comorbidities were analyzed. Results: Six of 19 (32%) patients showed right bundle block; 6 of 19 (32%) had AV nodal disease, including 4 patients with AV-block III; and 14 patients (73%) primarily presented with ventricular arrhythmias (including 3 with cardiac arrest). In all 19 patients cardiac EMB revealed elevated CD68 macrophages and CD3 T lymphocytes, and 7 of 19 were positive for granuloma (36,8%). Six of 6 patients (100%) undergoing PET CT showed acute inflammation. By analyzing the scar distribution, the most common locations were basal anteroseptal, basal inferoseptal, mid inferoseptal, mid inferior and the septal RV/RVOT. (septal substrate in 100%). There was a high correlation between the findings on the MRIs and low voltage in the electroanatomical mapping EAM). All patients received an immunosuppressive therapy. No patient died during follow-up, 1 patient had a high urgent heart transplant after withdrawal of steroid therapy. Conclusion: Chronic untreated inflammation may be the underlying pathophysiology for patients with unspecific cardiomyopathy and recurrent VA refractory to endocardial and epicardial ablation. Septal substrate in the EAM/MRI, elevated CD3 lymphocytes in the EBM and inflammation in the PET CT may indicate the possible diagnosis of cardiac sarcoidosis. Initializing immunosuppressive therapy in patients with this dedicated constellation with should be taken into consideration.
An magnetic resonance imaging-pathology correlation case report of cardiac sarcoidosis mimicking arrhythmogenic biventricular cardiomyopathy

B Michelle Kim,Melanie C Bois,Freddy Del-Carpio Munoz,Andrew N Rosenbaum,Ian C Chang

DOI: https://doi.org/10.1093/ehjcr/ytae395

2024-08-05

Abstract:Background: Cardiac sarcoidosis (CS) is a granulomatous disease that can manifest as conduction defects, ventricular arrhythmias, and heart failure. The diagnosis of CS is inherently difficult due to variable presentations; as such, endomyocardial biopsy is often required but lacks sensitivity due to patchy myocardial involvement. Moreover, the diagnostic criteria of CS and arrhythmogenic cardiomyopathy overlap, particularly in right-side dominant or biventricular presentations, which further complicates an already challenging differential diagnosis. Case summary: A 53-year-old man with no prior chronic medical conditions presented with ventricular tachycardia (VT) and heart failure with reduced ejection fraction. He was found to have biventricular cardiomyopathy and late gadolinium enhancement on cardiac magnetic resonance imaging, resulting in an initial diagnosis of arrhythmogenic cardiomyopathy. Implantable cardioverter-defibrillator was placed, but he was readmitted for recurrent VT 2 months later. Despite an aggressive VT therapy (combination of antiarrhythmic drugs, epicardial and endocardial ablation, and stellate ganglion block), he continued with refractory VT and developed cardiogenic shock. Extra-corporeal membrane oxygenation was initiated as a bridge to heart transplantation. Pathology of the explanted heart revealed the underlying disease to be CS. Discussion: Cardiac sarcoidosis can mimic arrhythmogenic biventricular cardiomyopathy and may be difficult to distinguish by the proposed diagnostic criteria. High clinical suspicion and thorough investigation are necessary for an earlier diagnosis and initiation of treatment.
Diagnostic and management strategies in cardiac sarcoidosis

Jasmine K Malhi,Chukwuka Ibecheozor,Jonathan Chrispin,Nisha A Gilotra,Jasmine K. Malhi,Nisha A. Gilotra

DOI: https://doi.org/10.1016/j.ijcard.2024.131853

IF: 4.039

2024-02-19

International Journal of Cardiology

Abstract:Cardiac sarcoidosis (CS) is increasingly recognized in the context of with otherwise unexplained electrical or structural heart disease due to improved diagnostic tools and awareness. Therefore, clinicians require improved understanding of this rare but fatal disease to care for these patients. The cardinal features of CS, include arrhythmias, atrio-ventricular conduction delay and cardiomyopathy. In addition to treatments tailored to these cardiac manifestations, immunosuppression plays a key role in active CS management. However, clinical trial and consensus guidelines are limited to guide the use of immunosuppression in these patients. This review aims to provide a practical overview to the current diagnostic challenges, treatment approach, and future opportunities in the field of CS.

cardiac & cardiovascular systems

Cardiac Sarcoidosis: Utilizing Cardiac MRI and PET-CT

Revealing The Enigma Of Cardiac Sarcoidosis: The Crucial Significance Of Advanced Imaging Modalities- A Case Report

Imaging of Cardiac Sarcoidosis: An Update and Future Aspects

Contemporary Diagnostics of Cardiac Sarcoidosis: The Importance of Multimodality Imaging

Sarcoid heart disease and imaging

Cardiac Sarcoidosis—Diagnostic and Therapeutic Challenges

[Cardiac sarcoidosis: a diagnostic and therapeutic challenge]

Exploring the latest advances in 18F-FDG PET/CT and cardiac magnetic resonance for imaging for cardiac sarcoidosis diagnosis

Cardiac sarcoidosis: diagnosis and management

Intense 68Ga-OncoFAP Uptake as a New Promising Diagnostic Biomarker in Cardiac Sarcoidosis

Risk Stratification in Cardiac Sarcoidosis With Cardiac Positron Emission Tomography: A Systematic Review and Meta-Analysis

Potential application of 68Ga-FAPI PET/CT for diagnosing cardiac sarcoidosis

Cardiac Sarcoidosis: A Comprehensive Clinical Review

FDG PET/CT Imaging of Sarcoidosis.

Isolated cardiac sarcoidosis: A clinical challenge

Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association

Hybrid Magnetic Resonance Positron Emission Tomography Is Associated With Cardiac-Related Outcomes in Cardiac Sarcoidosis

Can FDG-PET Imaging Identify Cardiac Sarcoidosis Disease Phenotypes?

Cardiac sarcoidosis in patients with recurrent ventricular arrhythmias refractory to endocardial ablation

An magnetic resonance imaging-pathology correlation case report of cardiac sarcoidosis mimicking arrhythmogenic biventricular cardiomyopathy

Diagnostic and management strategies in cardiac sarcoidosis